Clinical trials: Hemofiltration
Thromboprophylaxis, Critical Illness
Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.
Thromboprophylaxis is recommended for critically ill patients without contraindications and is usually achieved by the subcutaneous daily administration of a low dose of low molecular weight heparin (LMWH).
- Conditions
- Thromboprophylaxis, Critical Illness, Intensive Care (ICU)
- Trial name
- AKI-ENOXA (NCT07384598)
- Testing
- Anti-Xa profiles after the subcutaneous administration of a prophylactic dose of enoxaparin
- Volunteers
- 60 people
- Sponsor
- Clinique Saint Pierre Ottignies
Kidney Failure, Acute
Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration
Dialysis requires thinning of the blood to prevent clotting in the dialysis machine. Thinning of the blood is necessary but some forms of blood thinners may cause bleeding.
- Trial name
- NCT00583765
- Testing
- Regional citrate anticoagulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Alberta
Acute Renal Failure
Augmented Vs. Normal Renal Replacement Therapy in Severe Acute Renal Failure (ARF).
This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).
- Trial name
- NCT00221013
- Testing
- "augmented" CRRT regimen
- Where
- Australia
- Volunteers
- 1,508 people
- Sponsor
- The George Institute